Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Scott Bessent has given an update on the $2,000 stimulus checks President Donald Trump proposed paying out using the revenue raised from his tariffs. In an interview with ABC News on Sunday, the ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

WhatsApp chats have become central to both our work and personal lives. After winning our trust with its end-to-end encryption feature, the app has also become a storehouse of our personal photos and ...

Abstract: Java web applications have been extensively utilized for hosting and powering high-value commercial websites. However, their intricate complexities leave them susceptible to a critical ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

X has yet to give any official commentary regarding the issue, though its engineers have unofficially acknowledged the problem to the security researcher. But if you've been using X long enough, you ...

Abstract: Palindromic DNA has many interesting and functional properties, including the ability to form non-canonical DNA structures such as hairpins, cruciforms, and slipped strand structures.

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...